STAT

With new drug pricing legislation, Grassley and Wyden hint at the next steps for a powerful Senate committee

Sens. Chuck Grassley and Ron Wyden just dropped a new drug pricing bill — the first hints about how next year’s Senate Finance Committee, which they will lead, will take…
Sen. Chuck Grassley (R-Iowa)

WASHINGTON — A powerful, bipartisan pair of lawmakers introduced new legislation Tuesday that would give the government more power to make sure drug companies play by the rules of the Medicaid program.

It’s the first sign of how the duo, Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) intends

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer’s DTC Platform, Sandoz’s Feud With A U.K. Trade Group, And More
Pfizer filed a trademark application last month for a website and app providing medical information and mail-order pharmacy and telehealth services to U.S. patients.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.

Related Books & Audiobooks